P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sabizabulin (Primary) ; Everolimus; Exemestane
Indications Advanced breast cancer; Male breast cancer
Focus Therapeutic Use
Sponsors Veru Healthcare

Most Recent Events

22 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
22 Dec 2022 Planned End Date changed from 26 Feb 2024 to 26 May 2024.
22 Dec 2022 Planned primary completion date changed from 30 Dec 2023 to 30 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight